1. Home
  2. RGLS

as 07-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 132.2M IPO Year: 2012
Target Price: $11.00 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.45 EPS Growth: N/A
52 Week Low/High: $1.08 - $3.79 Next Earning Date: 08-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

RGLS Daily Stock ML Predictions

Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
CALSADA CRISPINA RGLS Chief Financial Officer Jan 18 '24 Sell $1.19 5,468 $6,510.20 5,782 SEC Form 4
Aker Christopher Ray RGLS Sr. VP & General Counsel Jan 18 '24 Sell $1.19 5,468 $6,510.20 10,056 SEC Form 4
Hagan Joseph P RGLS Chief Executive Officer Jan 18 '24 Sell $1.19 14,580 $17,358.95 57,112 SEC Form 4

Share on Social Networks: